36 results about "Hypotensive action" patented technology

Compounds shown by the above formula or salt thereof show a strong angiotensin II antagonistic activity and hypotensive action and CNS activity, and are useful as therapeutic agents of circulatory diseases such as hypertensive diseases and heart diseases (e.g. hypercardia, heart failure, cardiac infarction), strokes, cerebral apoplexy, nephritis, atherosclerosis, Alzheimer's disease, senile dementia, etc.

The invention relates to a beauty-slimming product containing dark green tea Euro-tium cristatum and a preparation method therof. The beauty-slimming product comprises Euro-tium cristatum which is active ingredient of Anhua dark green tea, and a plurality of extracts of medicine and food homologue, and has good real weight-reducing effect and the comprehensive function of lipid-lowering, glucose-lowering, and hypotensive action at the same time.

The invention relates to a pharmaceutical composition containing atenolol, amlodipine, or folic acid compounds and application thereof. The pharmaceutical composition contains an officinal dosage of the atenolol, an officinal dosage of the amlodipine or levamlodipine, an officinal dosage of the folic acid compounds, and a pharmaceutical acceptable carrier. The dosage of the atenolol is between 5 and 50 milligrams, the dosage of the amlodipine or the levamlodipine is between 0.5 and 5.0 milligrams, and the dosage of the folic acid type compounds is between 0.2 and 1.6 milligrams. The pharmaceutical composition has the following advantages: the pharmaceutical composition enhances the hypertension curative effect through multi-target synergistic hypotensive action, and reduces the taking dosage of the amlodipine simultaneously, that is, just about one fourth of the original dosage can achieve the same hypotensive effect and reduce the side effects and medical expenses; and more importantly, the pharmaceutical composition can effectively prevent and treat or delay various complications of high blood pressure cardiovascular and cerebrovascular diseases such as cerebrovascular disorder and the like through dual targets (Hcy and blood pressure) on the basis of reducing toxic side effects. Besides, the pharmaceutical composition ensures that patients can take medicine conveniently.

Sepsis is a complex, incompletely understood and often fatal disorder, typically accompanied by hypotension, that is considered to represent a dysregulated host response to an infection. Neurotensin (NT) is 13-amino-acid peptide that, among its multiple effects, induces hypotension. It is shown herein that plasma concentrations of NT are increased in humans with sepsis and in mice after caecal ligation and puncture (CLP), a model of sepsis. Mast cells can degrade NT through neurotensin receptor 1- and neurolysin-dependent mechanisms, diminishing the hypotensive effects of NT, reducing intraperitoneal NT concentrations, and improving survival. These findings show that mast cells can regulate NT concentrations, and identify NT as a biomarker and therapeutic target in sepsis.

The cyclodextrin inclusion compound of prazosin hydrochloride consists of prazosin hydrochloride and beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin in the mass ratio of 1/20-1/5, preferably 1/10. The supplementary material may include hydroxypropyl methyl cellulose-400, hydroxypropyl methyl cellulose-4000, lactose, microcrystalline cellulose, compressible starch, fine silica gel powder and magnesium stearate. The preparation process of the cyclodextrin inclusion compound of prazosin hydrochloride includes the steps of: mixing beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin with water to form suspension or solution; adding prazosin hydrochloride in the amount of 1/20-1/5 via fully mixing; pressure filtering, water washing, drying to obtain the solid inclusion compound. The present invention has the effects of smooth medicine release, smooth blood pressure reduction and convenient taking.

The invention discloses an application of cortex mori fatty oil in preparing a diuresis-inducing and blood pressure-reducing drug, and discusses a diuresis-inducing and blood pressure-reducing effect of the cortex mori fatty oil on SHR rat. According to the invention, the influences of the cortex mori fatty oil on urine volume of normal rats are observed by adopting a metabolic cage method of rats; and then the influences of the cortex mori fatty oil on urine volume and systolic blood pressure (SBP) of SHR rats are observed by selecting a spontaneously hypertensive rats (SHR) model and dosing for 7 days in repeated doses. The results show that compared with a control group (CMC-Na group), the cortex mori fatty oil has an obvious diuresis-inducing effect on both the normal rats and the SHR rats (P<0.01) and can significantly reduce systolic pressure of the SHR rats (P<0.01). Compared with the prior art, the invention determines that the cortex mori fatty oil components have the obvious diuresis-inducing and blood pressure-reducing effect, so that the use of the cortex mori fatty oil in preparing the diuresis-inducing and blood pressure-reducing drug is convenient, and the problem that much inconvenience is brought to patients who take the drug, due to unknown material basis of the cortex mori playing the diuresis-inducing and blood pressure-reducing effects, is overcome.

The invention provides a mytilus crassitesta oligopeptide and use thereof and belongs to the technical field of bioactive peptides. An amino acid sequence of the mytilus crassitesta oligopeptide is Leu-Ala-Ala-Ser-His or Tyr-Glu-Leu-His-Asp. The mytilus crassitesta oligopeptide provided by the invention has relatively high ACE inhibiting activity and is free of cytotoxicity, the content of an endogenous dilatation factor NO in blood vessel endothelial cells (HUVEC cells) can be increased, the content of an endogenous contraction factor ET-1 can be decreased, namely, the pressure release actionis exerted through affecting functions of the blood vessel endothelial cells. The mytilus crassitesta oligopeptide provided by the invention can be applied to preparation of health-care foods and/ormedicines with a blood pressure regulating action.

The invention provides an application of miRNA (micro-ribonucleic acid) miR-21 to glaucoma treatment and specifically provides an application of an active component. The active component is selected from the following groups: (a) miRNA from miRNA-21; (b) precursor miRNA; (c) polynucleotide; (d) an expression vector; (e) an agonist of miRNA in (a); the active component is used for preparing pharmaceutical composition which is used for preventing and/or treating glaucoma and/or reducing IOP (intraocular pressure). About 20% of pressure reduction can be realized by miRNA miR-21, and the pressurereduction effect keeps for 48 h which is longer than that of most drugs clinically.

Medicaments that depend on a combination of SGLT 2 inhibitors and antihypertensive drugs and which are useful in the treatment of diseases involving at least hypertension or diabetes mellitus as a risk factor of cardiovascular events, as well as methods of treating the diseases are provided. Since the present invention exhibits a superior hypotensive action that cannot be attained by any single antihypertensive drugs, the conventional problems associated with the use of two or more antihypertensive drugs in order to lower the blood pressure to the desired level can be solved. In addition, the present invention shows a marked therapeutic efficacy in diabetes mellitus, a disease associated with diabetes mellitus, or complications of diabetes mellitus, in particular, diabetic nephropathy. As a further advantage, the present invention is also useful for the treatment of diseases involving lowered renal function.

NMEG-αCGRP, a biologically active molecule, and systems and methods of use therefore, subcutaneous administration of NMEG-αCGRP, a non-toxic peptoid-peptide hybrid that possesses hypotensive action, employed as a therapeutic agent to treat and prevent various cardiovascular diseases, including, heart failure (pressure. as well as volume, overload), myocardial infarction, cardiomyopathy, and hypertension.

Disclosed is a pharmaceutical composition or food composition for the treatment or prevention of hypertension, containing a peptide isolated from a fraction of a flounder surimi hydrolysate as an active ingredient and is based on the finding that the flounder surimi has an effect of reducing blood pressure, and the hydrolysate of the flounder surimi, the fraction of the hydrolysate of the flounder surimi and peptides isolated from the fraction of the hydrolysate of the flounder surimi have an inhibition activity against an angiotensin I converting enzyme (ACE). Thus, peptides isolated from the fraction of the hydrolysate of the flounder surimi can be used for pharmaceutical compositions or food compositions for treating or preventing hypertension. Also, the present invention is based on the finding that the hydrolysate of the flounder surimi and peptides isolated therefrom have radical scavenging effect and a protective effect against oxidative stress and are thus capable of inhibiting ROS production, lipid peroxidation and apoptosis. Accordingly, peptides isolated from fractions of the hydrolysate of the flounder surimi can be used for food compositions for antioxidation.

The invention discloses an oligopeptide with a blood pressure reducing function, and a preparation method and application thereof, and belongs to the field of biological engineering. According to thetechnical scheme, the preparation method of the oligopeptide with the blood pressure reducing effect comprises the following steps: A, fermenting a soybean meal raw material to obtain fermented soybean meal, wherein the fermentation strain is butyric acid bacteria; B, carrying out secondary fermentation treatment on the fermented soybean meal in the step A with a cuttlefish crushed material to obtain a mixed base material, wherein the fermentation strain is butyric acid bacteria; C, carrying out enzymolysis on the mixed base material in the step B by adopting ultrasonic assisted enzymolysis toobtain an enzymolysis liquid; and D, filtering the enzymolysis liquid obtained in the step C, and performing purification and drying to obtain the oligopeptide with the blood pressure reducing effect. The oligopeptide provided by the invention has the beneficial effects that the selected oligopeptide provided by the invention contains characteristic amino acid for inhibiting the angiotensin I-converting enzyme (ACE), and distribution is uniform. The content of the amino acid is high, so that activity of the provided oligopeptide is high, the inhibition effect on the ACE is good, and the bloodpressure reducing effect is increased.

The invention provides a functional food with an antihypertensive effect and a preparation device thereof, and belongs to the technical field of health care products. The invention provides the functional food with an antihypertensive effect. The functional food is prepared from the following components in percentage by mass of 30-45% of carrot powder, 15-30% of blueberry powder, 3-6% of ginseng, 4-8% of hawthorn, 1-3% of cordyceps militaris, 4-8% of wax gourd and 3-5% of oyster extract. The carrot powder is used as a main raw material of the functional food for reducing blood pressure, can promote synthesis of epinephrine, increase coronary artery blood flow volume, has the effects of reducing blood pressure and diminishing inflammation, and can prevent cranial nerve aging, soften blood vessels and enhance human immunity by being matched with the blueberry powder; and meanwhile, ginseng, hawthorn, cordyceps militaris, wax gourd and oyster extract are matched, so that the antihypertensive effect can be enhanced, and the health-care functions of strengthening the spleen and stomach and enhancing the physical quality are also achieved. The invention further provides the preparation device of the functional food with the antihypertensive effect.

The invention relates to a plant extract which has the function of an angiotensin-converting enzyme inhibitor and the application thereof, belonging to the technical field of chemical component extraction of plants. The preparation process is as follows: rose is dried and the dried rosebuds are ground into powder; ethanol with concentration of 50 percent to 95 percent is used for extraction for 3 times; filtrations are carried out for 3 times and the extract is combined; the extract is decompressed and condensed into extractum; then ethanol with concentration of 50 percent is used for extraction for three times and the extract is combined, decompressed, cooled and dried. After pharmacology and pharmacodynamics tests, the analysis on the activity of lowering blood pressure of the rosebud ethanolic extract is carried out; the extract is found to be capable of effectively inhibiting the activity of angiotensin-converting enzyme and obviously lowering the blood pressure of hypertensive rats of two-kidney and one-clip type and being capable of being used for preparing medicines or health care products for curing or preventing hypertension. The preparation method of the extract is simple and practical and the plant extract prepared by the invention has obvious effect of lowering blood pressure and good application safety.

The invention belongs to the technical field of traditional Chinese medicine emplastrum, and particularly relates to an external traditional Chinese medicine compound emplastrum with an antihypertensive effect, and the external traditional Chinese medicine compound emplastrum with the antihypertensive effect is prepared from the following specific raw materials in parts by weight: 0.5-1.5 parts of uncaria, 0.5-1.5 parts of herba lycopi, 1-3 parts of radix puerariae and 0.5-1.5 parts of radix cyathulae. The traditional Chinese medicine compound plaster is directly and externally applied to the skin of a human body without being directly orally taken, so that the plaster is relatively convenient to use, the body is not slightly hurt in the process of reducing blood pressure by orally taking a blood pressure reducing medicine, and the effect of treating hypertension is greatly improved.